News Column

New Data from Ninth People's Hospital Illuminate Findings in Triterpenes (In vivo inhibition of hypertrophic scars by implantable...

July 22, 2014



New Data from Ninth People's Hospital Illuminate Findings in Triterpenes (In vivo inhibition of hypertrophic scars by implantable ginsenoside-Rg3-loaded electrospun fibrous membranes)

By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on Triterpenes have been presented. According to news reporting originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "Clinically, hypertrophic scarring (HS) is a major concern for patients and has been a challenge for surgeons, as there is a lack of treatments that can intervene early in the formation of HS. This study reports on a Chinese drug, 20-ginsenoside Rg3 (GS-Rg3), which can inhibit in vivo the early formation of HS and later HS hyperplasia by inducing the apoptosis of fibroblasts, inhibiting inflammation and down-regulating VEGF expression."

Our news editors obtained a quote from the research from Ninth People's Hospital, "Implantable biodegradable GS-Rg3-loaded poly(l-lactide) (PLA) fibrous membranes were successfully fabricated using co-electrospinning technology to control drug release and improve drug utilization. The in vivo releasing time of GS-Rg3 lasts for 3 months, and the drug concentration released in rabbits can be controlled by varying the drug content of the electrospun fibers. Histological observations of HE staining indicate that GS-Rg3/PLA significantly inhibits the HS formation, with obvious improvements in terms of dermis layer thickness, epidermis layer thickness and fibroblast proliferation. The results of immunohistochemistry staining and Masson's trichrome staining demonstrate that GS-Rg3/PLA electrospun fibrous membranes significantly inhibit HS formation, with decreased expression of collagen fibers and microvessels. VEGF protein levels are much lower in the group treated with GS-Rg3/PLA eletrospun membranes compared with other groups. These results demonstrate that GS-Rg3 is a novel drug, capable of inhibiting the early formation of HS and later HS hyperplasia."

According to the news editors, the research concluded: "GS-Rg3/PLA electrospun membrane is a very promising new treatment for early and long-term treatment of HS."

For more information on this research see: In vivo inhibition of hypertrophic scars by implantable ginsenoside-Rg3-loaded electrospun fibrous membranes. Acta Biomaterialia, 2013;9(12):9461-73. (Elsevier - www.elsevier.com; Acta Biomaterialia - www.elsevier.com/wps/product/cws_home/702994)

The news editors report that additional information may be obtained by contacting L. Cheng, Dept. of Plastic and Reconstructive Surgery, Ninth People's Hospital Affiliated to Medical School of Shanghai Jiao Tong University, 639 Zhi Zao Ju Road, Shanghai 200011, People's Republic of China. Additional authors for this research include X. Sun, C. Hu, R. Jin, B. Sun, Y. Shi, L. Zhang, W. Cui and Y. Zhang (see also Triterpenes).

Keywords for this news article include: Asia, Shanghai, Triterpenes, Ginsenosides, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Life Science Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters